Diabetes · Phase 2
Retatrutide: phase 2 diabetes study
What was tested?
Retatrutide compared with placebo and dulaglutide in adults with type 2 diabetes. ↗
Registered primary question: Change in HbA1c at week 24. ↗
What the reviewed report found
Journal year 2023 · Article summary reviewed 2026-09-15
At 24 weeks, reported glycated-hemoglobin changes ranged from -0.43 to -2.02 percentage points across retatrutide groups, compared with -0.01 for placebo and -1.41 for the active comparator. Reported body-weight change at 36 weeks ranged from -3.19% to -16.94% across retatrutide groups.↗
Keep in context: The report distinguishes 281 randomized participants from 275 included in efficacy analyses. Weight change at week 36 was a secondary endpoint. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 281 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years to 75 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2023-07-03; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Phase 2 type 2 diabetes trial
- Design in the report
- A randomized, double-blind, placebo- and active-comparator-controlled Phase 2 trial evaluated glycated hemoglobin at 24 weeks and body weight at 36 weeks.↗
- Participants in the report
- The trial randomized 281 adults with type 2 diabetes and elevated body-mass index at 42 U.S. centers; 275 were included in efficacy analyses.↗
- Limitations
- The sponsor-funded trial had 36-week follow-up, 79% completed treatment, and 84% of participants were White; those features limit conclusions about durability and generalizability.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of LY3437943 in Participants With Type 2 Diabetes ↗
Protocol identifier: 17774. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 d982d0da7ad7e0331422e07f197da1d47a7ed1febaa74be7d807bc6a8512ee2b.
PMID 37385280
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 37385280. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 766a11f2d979da96a8a2b79353159b0e0472215d1e391b8f8f5d09a142c5fdcd.